spacer
home > ebr > spring 2007 > pushing biobank standardisation
PUBLICATIONS
European Biopharmaceutical Review

Pushing Biobank Standardisation

Establishing an effective biomedical tissue management system is an integral part of moves to standardise and harmonise biobanking practices, explains Dr Achim Quandt of QIAGEN GmbH

In cancer research, as with other areas of biomedical research, a major issue facing researchers is the great variation in the methods employed by different labs for collecting, storing and analysing biological samples. This affects the quality and comparability of research data, and can only be resolved by the widespread adoption of standardised and quality-controlled protocols. Such protocols in case-control, cohort and other epidemiological studies are required to facilitate the discovery and validation of relevant disease biomarkers and, ultimately, the development of diagnostics and therapeutics.

Initiatives at the national and international level to standardise and harmonise biobanking practices have already begun. In Europe, the European Commission and the Wellcome Trust organised a conference in 2005 to discuss the current state of biobanks in Europe and to propose future strategies, including greater harmonisation of programmes and standards and greater standardisation of protocols. Proposals will be submitted to the 7th Framework Programme for Research and Technological Development (FP7), an EU programme with a budget of over ˆ50 billion to fund trans-European research.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Achim Quandt joined QIAGEN GmbH, a leading supplier of sample and assay technologies, as Global Product Manager for gene expression analysis products in April 2000. His current role involves global responsibility for the biomedical research market segment, including biomedical tissue management and biobanking. Prior to this, he spent five years working in sales and marketing at molecular diagnostics companies. Achim has a PhD in Molecular Biology and has studied at Bielefeld University, Germany, and the University of Edinburgh, UK.
spacer
Dr Achim Quandt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.

Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement